HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BDX

Becton, Dickinson and Company (S&P 500)

Healthcare — Medical Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Buy 2.1 / 5 12 analysts
$166.34
+$7.42 (+4.67%)
Target: $180.25 (8.4%)
Sign in to add BDX to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$45.83B
P/E Ratio (TTM)28.98
Forward P/E12.36
EPS (TTM)$5.74
Dividend Yield2.64%
Profit Margin5.12%
Revenue Growth5.20%
ROE6.67%
Debt/Equity71.60
Recommendation Buy 2.1
Analyst Target$180.25
Analysts12
Indexes S&P 500

Technical Indicators

RSI (14)71.9
Beta0.27
SMA 20$155.05
SMA 40$151.29
52-Week High$187.35
52-Week Low$127.59
50-Day Avg$149.88
200-Day Avg$154.70
Avg Volume$2.71M
Volume$1.94M

Performance Analysis

BULLISH

BDX shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 65% of its 52-week range.
- RSI at 71.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 5.2% year-over-year.
+ Wall Street consensus is "Buy" from 12 analysts.
+ Average analyst target of $180.25 implies 8.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:00 UTC

Back to Screener Export Report